Jiangsu Hengrui Pharmaceuticals announced that the company and its subsidiary Fujian Shengdi Pharmaceutical Co., Ltd. received the "Notice of Drug Clinical Trial Approval" for HRS-4729 injection issued by the National Medical Products Administration. This drug is an independently developed peptide drug and a GLP-1R/GIPR/GCGR tri-agonist, suitable for patients with obesity or overweight. So far, approximately 19.56 million yuan has been invested in the research and development costs for HRS-4729 injection.
恒瑞医药：HRS-4729注射液获临床试验批准
Jiangsu Hengrui Pharmaceuticals: HRS-4729 injection has received clinical trial approval.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Investment Course
Choose stocks based on financial reports
Quickly master financial season learning guidelines
When the financial season comes, company stock prices are the most likely to rise and fall, and many excellent investors will see the financial season as a good
How to view Tesla's performance in January 2025? Pay attention to these four key points.
It's earnings season for US stocks again. The performance of giant companies not only affects their own stock prices but also influences the overall trend of th
In 【2024.11】, surged more than 0.04 million times, achieving the title of stock god Buffett! How do you view Berkshire's performance?
When it comes to legendary figures in the investment world, the name of Warren Buffett, the helm of Berkshire Hathaway, is definitely unavoidable. $Berkshire Ha